Antibodies to human IL-1β

Details Antibodies to human IL-1β Antibodies to human IL-1β

2011-08-09

2011-08-09

Kemmerer, Elizabeth C (Department: 1646)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S069100, C435S320100, C435S325000, C435S326000, C435S335000, C435S252300, C435S254110, C536S023100, C536S023530, C530S387100, C530S387300, C530S388230

Reexamination Certificate

active

07993878

ABSTRACT:
An IL-1β binding molecule, in particular an antibody to human IL-1β, especially a human antibody to human IL-1β is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides.

REFERENCES:
patent: 4935343 (1990-06-01), Allison et al.
patent: 5348858 (1994-09-01), Uetsuki et al.
patent: 5470578 (1995-11-01), Aoki et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 6309636 (2001-10-01), do Couto et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 218531 (1987-04-01), None
patent: 0 267 611 (1988-05-01), None
patent: 0 364 778 (1990-04-01), None
patent: 0 403 1560 (1990-12-01), None
patent: 0 256 055 (1991-08-01), None
patent: 0 323 997 (1993-04-01), None
patent: 0 338 841 (1995-03-01), None
patent: 0 438 474 (1996-05-01), None
patent: 0491031 (1996-05-01), None
patent: 0 463 151 (1996-06-01), None
patent: 0 546 073 (1997-09-01), None
patent: 88/01649 (1988-03-01), None
patent: WO 90/06371 (1990-06-01), None
patent: 90/07861 (1990-07-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 91/09968 (1991-07-01), None
patent: WO 92/01059 (1992-01-01), None
patent: 95/01997 (1995-01-01), None
patent: WO 95/01197 (1995-01-01), None
patent: WO 99/42075 (1999-08-01), None
patent: WO 01/53353 (2001-07-01), None
Portolano et al., J. Immunol., 1993, vol. 150(3):880-887.
Clackson et al., Nature, 1991, vol. 352:624-628.
Knappik et al., J. Mol. Biol., 2000, vol. 296(1):57-86.
Rudikoff et al., Proc. Natl. Acad. Sci. USA, 1982, vol. 79:1979-1983.
Wu et al., J. Mol. Biol., 1999, vol. 294(1):151-162.
Roth R.I., J. Am. Pharm. Assoc. (Wash.), May-Jun. 2001, vol. 41(3): 383-391.
Eck, S. L. and Wilson, J. M.,1996, in: Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, McGraw-Hill, New York.
Boraschi et al., “Differential Inhibition of IL-1β Activities and Receptor Binding by Monoclonal Antibodies Mapping Within a Discrete Region of the Protein”, Lymphokine Research, vol. 10, No. 5, pp. 377-384, (1991).
Herzbeck et al., “Functional and Molecular Characterization of a Monoclonal Antibody against the 165-186 Peptide of Human IL-1β”, Scand. J. Immunol. vol. 30, pp. 549-562, (1989).
D'Ettorre et al., “Functional epitope mapping of human interleukin-1β by surface plasmon resonance”, Eur. Cytokine Netw., vol. 8, No. 2, pp. 161-171, (1997).
Jackson et al., “In Vitro Antibody Maturation-Improvement of a High Affinity, Neutralizing Antibody Against IL-1β”, Journal of Immunology, vol. 154, No. 7, pp. 3310-3319, (1995). [XP-000941315].
International Search Report, (Apr. 10, 2002).
British Search Report, (Jan. 24, 2001).
Straubinger et al., “Two Unusual Human Immunoglobulin V Kappa Genes”, Biol Chem, Hoppe-Seyler 369, vol. 7, pp. 601-607, (1988).
D'Ettore et al., “Functional Epitope Mapping of Human Interleukin-1β by Surface Plasmon Resonance”, Eur. Cytokine Netw., vol. 8, No. 2, pp. 161-171, (1997).
Massone et al., “Mapping of Biologically Relevant Sites on Human IL-1β Using Monoclonal Antibodies”, The Journal of Immunology, vol. 140, No. 11, pp. 3812-3816, (1988).
Ward et al, “Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted FromEscherichia coli”, Nature, vol. 341, pp. 544-546, (1989).
Muyldermans et al., “Recognition of Antigens by Single-Domain Antibody Fragments: The Superfluous Luxury of Paired Domains”, Trends in Biochemical Sciences, vol. 26, No. 4, pp. 230-235, (2001).
Van den Beucken et al., “Building Novel Binding Ligands to B7.1 and B7.2 Based on Human Antibody Single Variable Light Chain Domains”, J. Mol. Biol., vol. 310, pp. 591-601, (2001).
Cacia et al., Biochemistry, 1996, vol. 35, pp. 1897-1903.
Rudikoff et al., Proc. Natl. Acad. Sci, USA, 1982, vol. 79: 1979-1983.
Alberts et al., The Cell, 2002, Garland Science, 4th edition, esp. pp. 161, Fig. 3-42.
Wang Z et al., “Humanization of a mouse monoclonal antibody neutralizing TNF-α by guided selection”, Journal of Immunological Methods, vol. 241, pp. 171-184, (2000).
Queen, C et al., “A humanized antibody that binds to the interleukin 2 receptor”, Proc. Natl. Acad. Sci., vol. 86, pp. 10029-10033, (1989).
Rader C et al., “A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries”, Proc, Natl. Acad. Sci., vol. 95, pp. 8910-8915,(1998).
Davies S et al., “Engineering Mammalian Cells for Recombinant Monoclonal Antibody Production”, Department of Chemical and Process Engineering, University of Sheffield, pp. 153-173, (2009).
Ward E S et al.,“Binding activities of a repertoire of single immunoglobulin variable domains secreted fromEscherichia coli”, Letters to Nature, vol. 341, pp. 544-546, (1989).
Muyldermans S et al., “Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains”, Trends in Biochemical Sciences, vol. 26, No. 4. pp. 230-235, (2001).
Riechmann L et al., “Reshaping human antibodies for therapy”, Nature, vol. 332, pp. 323-327, (1988).
Borrebaeck et al., “Kinetic Analysis of Recombinant Antibody-Antigen Interactions: Relation Between Structural Domains and Antigen Binding”, Nature, vol. 10(6), pp. 697-698, (1992).
Matsuda F. et al., Journal of Experimental Medicine, vol. 188 (11) pp. 2151-2162. (1998).
Philip L. Simon et al., “Mapping of Neutralizing Epitopes and the Receptor Bindng Site of Human Interleukin 1 β”, J. bio. Chem., vol. 268, No. 13, pp. 9771-9779, (1993).
Reiter et al., J. Mol. Biol. vol. 290, pp. 685-698, (1999).
Riechmann, Muyldermans, “Single domain antibodies: comparison of camel VH and camelised human VH domains”, Journal of Immu. Methods, vol. 231, pp. 25-38, (1999).
Bigio et al., “One-step immunoaffinity purification of bioactive human recombinant IL-1 β with a monocional antibody directed to a well-exposed domain of the protein”, Journal of Immunological Methods, vol. 123, pp. 1-8. (1989).
Pascalls et al., “Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligan Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody”, The Journal of Immunology, vol. 169, pp. 3076-3084. (2002).
Panka at al , “Variable region framework differences result in decreased or increased affinity of variant anti-gigoxin antibodies”, Proc Natl. Acad Sci USA, vol. 85, pp. 3080-3084, (1988).
Colman et al.. “Effects of amino acid sequence changes on antibody-antigen interactions”, Research in Immmunology, vol. 145(1), pp. 33-36, (1994).
Abaza et al., J. of Protein Chem., vol. 11 (5), pp. 433-444, (1992).
Sauder, D.N. “Interleukin 1”, Archives of Dermatology, vol. 125, McMaster University, Department of Medicine, Division of Dermatology, Hamilton, Canada, pp. 679-682, May 1989.
Bellini AV. et al., “Production process of recombinant. IL-1beta fromBacillus subtilis: comparison between intracellular and exocellular expression”, Journal of Biotechnology, vol. 18, pp. 177-192, 1991.
Feldman et al., “Anti-TNFalpha Therapy is Useful in Rheumatoid Arthritis and Crohn's Disease: Analysis of the Mechanism of Action Predicts Utility in Other Diseases”, Transplant. Proc., vol. 30, pp. 4126-4127, 1998.
Cochlovius et al., Therapeutics Antibodies—After Years of promise, magic bullets appear to be on the upswing, Modern Drug Discover, pp. 33-38, 2003.
Van Noort et al., &#x

Affiliated with

Also associated with

Rating

Antibodies to human IL-1β does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to human IL-1β, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to human IL-1β will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2772808